ArticleFrontiers in bioengineering and biotechnology2026
Effect of combining low intensity-extracorporeal shockwave therapy with platelet-rich plasma among female patients with interstitial cystitis: a prospective single-arm pilot study.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial cystitis (IC) is a disease comprised of multiple symptoms, included persistent bladder pain syndrome (BPS), frequent urination, and urgency without getting infection or other identifiable causes. Methods: In our study, 25 female patients diagnosed with IC/BPS, the patients were performed low-intensity extracorporeal shockwave therapy (LI-ESWT) once a week for 8 weeks. The application sites for LI-ESWT are located above the pubic bone, in the middle and on both sides, with each session lasting about 20-30 min. High dosage of platelet-rich plasma (PRP) injections were administered in weeks 1, 5, and 9. All subjects had a baseline, 1-month and 6-month post-treatment assessment that included validated questionnaires and voiding diaries. Urodynamic studies were conducted at baseline and the 6-month follow-up after treatment. Results: We observed an 80% efficacy rate. Then, we showed significant improvements in VAS, OABSS, UDI-6, IIQ-7, and POP at the 1-month follow-up. However, only the ICIQ showed significant improvement at the 6-month follow-up. We further examined the urodynamic parameters and MCC revealed significant difference at 6-month follow-up. The voiding diaries, which tracks the number of urinations, voided volume, maximum volume, and nocturia significant improved at 1-month follow-up while only maximum volume showed improvement at the 6-month follow-up. Finally, ICSI, ICPI, and OSS, all showed significant differences at both the 1-month and 6-month follow-ups. Conclusion: The results of our study suggested that the combination treatment of PRP and LI-ESWT might show a therapeutic efficacy to IC/BPS patients, However, the follow-ups at 1 month and 6 months post-treatment suggested that the treatment needs to be administered again over time to maintain its effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.